Found: 68
Select item for more details and to access through your institution.
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1051, doi. 10.1007/s10637-022-01253-3
- By:
- Publication type:
- Article
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 159, doi. 10.1007/s10637-014-0167-5
- By:
- Publication type:
- Article
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
- Published in:
- 2018
- By:
- Publication type:
- research
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
- Published in:
- Nature Communications, 2016, v. 7, n. 1, p. 10582, doi. 10.1038/ncomms10582
- By:
- Publication type:
- Article
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.
- Published in:
- Case Reports in Oncology, 2019, v. 12, n. 1, p. 260, doi. 10.1159/000498985
- By:
- Publication type:
- Article
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 312, n. 17, p. 1744, doi. 10.1001/jama.2014.13943
- By:
- Publication type:
- Article
B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma.
- Published in:
- Current Oncology Reports, 2010, v. 12, n. 3, p. 146, doi. 10.1007/s11912-010-0095-2
- By:
- Publication type:
- Article
Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness.
- Published in:
- Essays in Biochemistry, 2022, v. 66, n. 4, p. 291, doi. 10.1042/EBC20220003
- By:
- Publication type:
- Article
Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 4, p. 2123, doi. 10.3390/ijms25042123
- By:
- Publication type:
- Article
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.
- Published in:
- Journal of Neuro-Oncology, 2017, v. 133, n. 2, p. 435, doi. 10.1007/s11060-017-2455-3
- By:
- Publication type:
- Article
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
- Published in:
- Nature Communications, 2018, p. 1, doi. 10.1038/s41467-018-06067-7
- By:
- Publication type:
- Article
COVID-19 and Cancer: a Comprehensive Review.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 5, p. 1, doi. 10.1007/s11912-020-00934-7
- By:
- Publication type:
- Article
Biological challenges of BRAF inhibitor therapy
- Published in:
- Molecular Oncology, 2011, v. 5, n. 2, p. 116, doi. 10.1016/j.molonc.2011.01.005
- By:
- Publication type:
- Article
Intratumoral Immunotherapy—Update 2019.
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. e423, doi. 10.1634/theoncologist.2019-0438
- By:
- Publication type:
- Article
Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel.
- Published in:
- Oncologist, 2014, v. 19, n. 6, p. 616, doi. 10.1634/theoncologist.2014-0011
- By:
- Publication type:
- Article
Is Renal Thrombotic Angiopathy an Emerging Problem in the Treatment of Ovarian Cancer Recurrences?
- Published in:
- Oncologist, 2012, v. 17, n. 12, p. 1534, doi. 10.1634/theoncologist.2011-0422
- By:
- Publication type:
- Article
Evolving Strategies for the Management of Hand--Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib.
- Published in:
- Oncologist, 2008, v. 13, n. 9, p. 1001, doi. 10.1634/theoncologist.2008-0131
- By:
- Publication type:
- Article
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 8, p. 1904, doi. 10.1002/cam4.1140
- By:
- Publication type:
- Article
Optimal Practices for Suspected Nodal Melanoma—The Role of the General Surgeon.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-21619-0
- By:
- Publication type:
- Article
The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 12, p. 2191, doi. 10.1002/cncr.35247
- By:
- Publication type:
- Article
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.
- Published in:
- 2015
- By:
- Publication type:
- Abstract
Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM).
- Published in:
- Journal of Translational Medicine, 2015, v. 13, p. 1, doi. 10.1186/1479-5876-13-S1-K8
- By:
- Publication type:
- Article
Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems.
- Published in:
- Immunological Reviews, 1998, v. 165, n. 1, p. 47, doi. 10.1111/j.1600-065X.1998.tb01229.x
- By:
- Publication type:
- Article
Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1 AX driver mutations in melanoma and across the cancer spectrum.
- Published in:
- Pigment Cell & Melanoma Research, 2016, v. 29, n. 4, p. 470, doi. 10.1111/pcmr.12482
- By:
- Publication type:
- Article
A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2016, v. 29, n. 1, p. 101, doi. 10.1111/pcmr.12394
- By:
- Publication type:
- Article
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
- Published in:
- Pigment Cell & Melanoma Research, 2015, v. 28, n. 5, p. 611, doi. 10.1111/pcmr.12383
- By:
- Publication type:
- Article
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
- Published in:
- Journal of Mass Spectrometry, 2008, v. 43, n. 1, p. 42, doi. 10.1002/jms.1268
- By:
- Publication type:
- Article
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 17, p. 2684, doi. 10.1002/cncr.28767
- By:
- Publication type:
- Article
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 24, p. 6055, doi. 10.1002/cncr.27668
- By:
- Publication type:
- Article
Combination Targeted Therapy in Advanced Renal Cell Carcinoma.
- Published in:
- Cancer (0008543X), 2009, v. 115, n. 10, p. 2368, doi. 10.1002/cncr.24234
- By:
- Publication type:
- Article
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy).
- Published in:
- 2021
- By:
- Publication type:
- journal article
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
- Published in:
- 2020
- By:
- Publication type:
- journal article
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Anti-IL6R role in treatment of COVID-19-related ARDS.
- Published in:
- 2020
- By:
- Publication type:
- editorial
T-VEC Boosts Immunotherapy in Phase 1 Trials.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2017, v. 8, p. 41
- By:
- Publication type:
- Article
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2016, v. 23, n. 13, p. 4169, doi. 10.1245/s10434-016-5286-0
- By:
- Publication type:
- Article
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
- Published in:
- Head & Neck, 2011, v. 33, n. 12, p. 1804, doi. 10.1002/hed.21478
- By:
- Publication type:
- Article
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.958043
- By:
- Publication type:
- Article
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
- Published in:
- British Journal of Clinical Pharmacology, 2018, v. 84, n. 1, p. 112, doi. 10.1111/bcp.13424
- By:
- Publication type:
- Article
Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response.
- Published in:
- Clinical Pharmacology, 2022, v. 14, p. 69, doi. 10.2147/CPAA.S369008
- By:
- Publication type:
- Article
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors †.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 4913, doi. 10.3390/cancers15204913
- By:
- Publication type:
- Article